Core Viewpoint - ClearPoint Neuro has successfully completed the acquisition of IRRAS Holdings, enhancing its commercial scale and operational leverage while supporting its long-term strategy in CNS drug delivery innovation [1][4]. Acquisition Details - The acquisition involved a payment of $5.0 million in cash and the issuance of 1,325,000 shares of common stock to IRRAS shareholders, along with a revenue share on net sales of certain IRRAS products for specific periods [2]. - IRRAS' operational results will be included in ClearPoint Neuro's consolidated results starting from the fourth quarter of 2025 [2]. Strategic Benefits - The acquisition introduces the IRRAflow active fluid-exchange system, which modernizes the management of intracranial bleeding, and adds over 50 active customers along with a robust commercial team [3]. - The integration of IRRAS is expected to expand ClearPoint Neuro's presence in neurocritical care and complement its existing neurosurgical technologies and drug delivery platforms [3]. Leadership Insights - The CEO of ClearPoint Neuro emphasized that the acquisition is a significant milestone in building a leading platform for neuro drug delivery, enhancing the company's ability to serve patients and partners [4]. - The former CEO of IRRAS expressed confidence in ClearPoint Neuro's capability to advance the IRRAflow technology and extend its clinical impact [4].

Core Insights - ClearPoint Neuro, Inc. will participate in multiple global healthcare conferences in the fourth quarter of 2025, showcasing its commitment to engaging with investors and stakeholders in the healthcare sector [1][2]. Conference Participation - The company is scheduled to present at the following conferences: - 2025 UBS Global Healthcare Conference on November 10, 2025 [2] - 2025 Stifel Healthcare Conference on November 13, 2025 [2] - 37th Annual Piper Sandler Healthcare Conference on December 3, 2025 [2] - ClearPoint Neuro management will be available for in-person investor meetings at these events [2]. Company Overview - ClearPoint Neuro specializes in device, cell, and gene therapy-enabling technologies, providing precise navigation solutions for the brain and spine [3]. - The flagship product, the ClearPoint Neuro Navigation System, has received FDA clearance and is CE-marked, indicating its regulatory compliance and market readiness [3]. - The company collaborates with healthcare and research centers across North America, Europe, Asia, and South America, and partners with leading pharmaceutical and biotech firms [3]. - Thousands of procedures have been supported by the company's clinical specialist team, highlighting its operational experience and market presence [3].